495076-64-7
495076-64-7
Chemical Structure
Org 25543 hydrochloride
- CAS No.: 495076-64-7
- Formula:C24H33ClN2O4
- Molecular Weight:448.98
IUPAC Name: 4-(benzyloxy)-N-((1-(dimethylamino)cyclopentyl)methyl)-3,5-dimethoxybenzamide hydrochloride
InChIKey: NIPQJILJYQVZJR-UHFFFAOYSA-N
SMILES: COC(C=C(C(NCC1(CCCC1)N(C)C)=O)C=C2OC)=C2OCC3=CC=CC=C3.[H]Cl
Biological Activity: Org 25543 hydrochloride is a selective and irreversible GlyT2 inhibitor (IC50: 16 nM). Org 25543 hydrochloride has analgesia effect. Org 25543 hydrochloride ameliorates mechanical allodynia after partial sciatic nerve ligation injury in mice[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Org 25543 hydrochloride | 99.93% | Org 25543 hydrochloride is a selective and irreversible GlyT2 inhibitor (IC50: 16 nM). Org 25543 hydrochloride has analgesia effect. Org 25543 hydrochloride ameliorates mechanical allodynia after partial sciatic nerve ligation injury in mice. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Org 25543 hydrochloride (Standard) | Org 25543 hydrochloride (Standard) is the analytical standard of Org 25543 (hydrochloride) (HY-107527). This product is intended for research and analytical applications. Org 25543 hydrochloride is a selective and irreversible GlyT2 inhibitor (IC50: 16 nM). Org 25543 hydrochloride has analgesia effect. Org 25543 hydrochloride ameliorates mechanical allodynia after partial sciatic nerve ligation injury in mice. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Caulfield WL, et al. The first potent and selective inhibitors of the glycine transporter type 2. J Med Chem. 2001 Aug 16;44(17):2679-82. [Content Brief]
- [2]. Morita K, et al. Spinal antiallodynia action of glycine transporter inhibitors in neuropathic pain models in mice. J Pharmacol Exp Ther. 2008 Aug;326(2):633-45. [Content Brief]
- [3]. Mohammadzadeh A, et al. Pharmacological Evidence on Augmented Antiallodynia Following Systemic Co-Treatment with GlyT-1 and GlyT-2 Inhibitors in Rat Neuropathic Pain Model. Int J Mol Sci. 2021 Mar 1;22(5):2479. [Content Brief]
